Multilink™ Technology
Multilink™ technology is a new peptidic cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high drug-to-antibody ratio (DAR) and high stability.
In short
This unique and innovative technology allows the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly effective and well-tolerated linker platform is available for use by other specialty biotech or pharmaceutical companies to generate proprietary, clinical-stage ADCs.
The Multilink™ technology allows for the creation of high DAR and high stability ADCs.
Debiopharm’s ADC Portfolio
Our value proposition
Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential, including Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS), Debio 0532, an HER3-targeted ADC for solid tumors and Debio 0633, a potential first-in-class with a novel target. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other further undisclosed targets. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and dual payloads or degraders, leveraging our solid development experience to accelerate ADC products to patients.
Our Ongoing Partnerships
